The Global Glioblastoma treatment market size reached US$ 2.74 billion in 2024 and is expected to reach US$ 5.77 billion by 2033, growing at a CAGR of 8.7% during the forecast period 2025-2033 As per the Datam Intelligence Report.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/glioblastoma-treatment-market?oppratik

Recent Product launch in U.S Market-

✅ August 6, 2025 - Modeyso (Dordaviprone) by Jazz Pharmaceuticals received FDA accelerated approval in the U.S. for H3 K27M-mutated diffuse midline glioma, marking the first systemic therapy directly targeting this mutation in glioblastoma patients.

✅ August 25, 2025 - ANKTIVA NK-Cell Therapy (Investigational) by ImmunityBio demonstrated 100% disease control in 5 out of 5 recurrent glioblastoma patients during an early-phase clinical trial, with FDA submission expected soon.

Recent Product Launchi In Japan market-

✅Japan: In July 2025, Japanese regulator granted "SAKIGAKE" designation to a peptide vaccine for GBM in Japan

Recent Mergers & Acquisitions (2025)

-In March 2025, Jazz Pharmaceuticals acquired Chimerix for $935 million, obtaining Modeyso (dordaviprone) which was later approved to be used in the U.S..​

-Earlier, Merck & Co. had acquired Modifi Biosciences to develop glioblastoma-targeted therapy MOD-246, which targets temozolomide-resistant glioblastoma.

-There were no reported significant new M&As specific to glioblastoma in Japan within the past 5 months. There were, however, some oncology focused consolidations (such as Concentra Biosciences acquisition of Elevation Oncology in July 2025) supporting capital allocation towards innovation in neuro-oncology..

Recent Investments (May-October 2025)

-Alpheus Medical raised $52 million in Series B (May 2025) to develop its sonodynamic therapy (SDT) for patients with newly diagnosed GBM in North America.

-The Innovation GBM consortium has provided $170 million in total investment since 2023, with additional rounds in mid-2025 to support nine GBM-focused startups.

-A UK Government-backed £70 million initiative was announced in September 2025 to accelerate the clinical research phase of drug trials for glioblastoma in 2026.

Key Players-

Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries, Ltd., F. Hoffman-La Roche, Novartis AG and Pfizer.

Research Process:

Both primary and secondary data sources have been used in the global Glioblastoma Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

DataM Intelligence has published a new research report on "Glioblastoma Treatment Market Size 2025". The report explores comprehensive and insightful Information.The global glioblastoma treatment market report delivers a detailed analysis with 45 key tables, more than 41 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

Key Segments:

By Treatment Type- Chemotherapy, Immunotherapy, Electric-field therapy, Others

By Type of Molecule- Small Molecules, Biologics

By Route of Administration- Oral, Parenteral

By End-User- Hospitals, Clinics, Others

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

FDA and Regulatory Approvals (Recent Months)

August 6, 2025 - The Food and Drug Administration (FDA) approved Modeyso (Dordaviprone) for use in diffuse midline glioma with H3 K27M mutation (Jazz Pharmaceuticals).

January 2025 - The FDA also approved Novocure's Head Flexible Electrode Arrays, Optune Gio, for adult patients with glioblastoma.

April 2025 - Alpha Tau Medical received FDA Investigational Device Exemption (IDE) approval for the Alpha DaRT pilot study on patients with recurrent glioblastoma.

Latest News:

October 2025 - NBTS-funded UCLA research entered clinical trials addressing resistance mechanisms in glioblastoma.​

August 2025 - ImmunityBio ANKTIVA NK-cell therapy showed complete disease control in recurrent GBM cases.​

June 2025 - ASCO 2025 highlighted dual-target CAR-T therapies slowing GBM growth.

Impact of COVID-19 (Glioblastoma Market)

Delays in data resulted from disruptions to early-phase clinical trial enrollment due to nursing home lockdowns.

Rapid adoption of telemedicine and decentralized clinical trials improved follow-up care.

Post pandemic, there is a growing focus on domestic manufacturing and supply chain resiliency for oncology drugs.

FAQ's

Q1: What is the current size of the Glioblastoma Treatment Market?

A: The Glioblastoma Treatment Market stood at US$ 2.74 billion in 2024 and is set to experience remarkable growth, reaching US$ 5.77 billion by 2033

Q2: How fast is the Glioblastoma Treatment Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 8.7% from 2025 to 2033

Q3: Which regions are dominating the Glioblastoma Treatment Market and which are fastest-growing?

A: North America dominating the Glioblastoma Treatment market.

Request for 2 Days FREE Trial Access:

https://www.datamintelligence.com/reports-subscription?oppratik

✅ Competitive Landscape

✅ Technology Roadmap Analysis

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Consumer Behavior & Demand Analysis

✅ Import-Export Data Monitoring

✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:

https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.